Privately-held PurMinds BioPharma (Burlington, Ontario, Canada) recently announced an investment in the psychedelic drug company IMIO Life Ltd., a subsidiary of Tel Aviv–based Nextage Therapeutics Ltd. (TASE:NXTG). Nextage Therapeutics is itself a division of the pharmaceutical company Nextar Chempharma Solutions (Ness Ziona, Israel). We reached out to PurMinds’ chief strategy and financial officer, Aron Buchman,…